Prostat Kanserinde Androjen Deprivasyon Tedavisinin Metabolik Ve Hematolojik Parametrelere Olan Uzun Dönem Etkileri

Year 2013, Volume: 8 Issue: 3, 37 - 41, 01.08.2013

Uzun Dönem Etkileri Haşmet Sarıcı Cem Nedim Yücetürk Berat Cem Özgür Onur Telli Ahmet Metin Hasçiçek Tolga Karakan Emre Huri Muzaffer Eroğlu

Abstract

Amaç: Bu çalışmada amacımız androjen deprivasyon tedavisi ADT alan prostat kanserli hastalardaki hematolojik ve metabolik uzun dönem etkileri analiz etmektir. Gereç ve Yöntemler: Kliniğimizde son 3 yılda metastatik prostat kanseri tanısıyla LHRH agonisti ile androjen deprivasyon tedavisi alan 50 hasta retrospektif olarak değerlendirildi. Hastaların ortalama yaşı 74.8 yıldı. Hastaların tedavi başlangıcındaki ve sonraki 1., 2., ve 3. yıl serum glukoz , total kolesterol , trigliserid , serum lipoproteinleri LDL, HDL ve tam kan sayımı parametreleri karşılaştırıldı. Bu çalışmada istatistiksel analiz SPSS for Windows Version 15.0 paket programıyla yapıldı. p0.05 . Serum total kolesterol, trigliserid ve low-densiy lipoprotein LDL seviyelerinde istatistiksel olarak anlamlı artış izlendi, sırasıyla p

Keywords

prostat kanseri , andojen deprivasyon tedavisi ADT , metabolik yan etkiler , hematolojik yan etkiler

Long-term effects of androgen deprivation therapy in prostate cancer patients on me- tabolic and hematologic parameters

Abstract

Purpose: In this study, we aimed to analyze metabolic and hematologic long term effects in prostate cancer patients receiving andogen deprivation therapy ADT . Material and Methods: In last 3 years 50 patients with metastatic prostate cancer treated with LHRH agonists in our department were retrospectively evaluated. The median age was 74.8 years. Serum levels of glucose, total cholesterol, lipoproteins LDL, HDL and hemogram parameters, that measured at baseline and first, second and third years after treatment, were compared. The statistical analysis in this study was performed with SPSS for Windows Version 15.0 Inc., Chicago, IL . p0,05 . Serum total cholesterol TC , triglyceride TG , low-density lipoprotein LDL levels increased significantly, p0,05 . When hematologic parameters were eveluated, LHRH agonists significantly decreased hemoglobin levels, median decrease was about 1 gr/dl p

Keywords

prostate cancer , andogen deprivation therapy , metabolic changes , hematologic changes

References

• SEER: Surveillance, Epidomology and End Results (SEER): Stat Fact Sheets: Prostate Cancer. 2008.
• Huggins C, Stevens RF Jr, Hodges CV. Studies on prostatic cancer. The effects of castration on advanced carcinoma of prostate gland. Arch Surg 1941; 43(1):209-23.
• Bolla M, Gonzales D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with raiotherapy and goserelin. N Engl J Med. 1997; 337(5):295- 300.
• D’Amico AV, Manola J, Loffredo M, et al. 6 Month andro- gen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292(7):821-7.
• Messing EM, Manola J, Yao J, et al. Immediate versus defer- red androgen deprivation treatment in patients with node positive prostate cancer after radical prostatectomy and pel- vic lymphadenectomy. Lancet Oncol 2006; 7(6):472-9.
• Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wenberg DC. The rising prevalence of androgen deprivati- on among older American men since the advent of prosta- te-spesific antigen testing: a population-based cohort study. BJU Int 2006; 98(5):973-8.
• Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone ago- nists for the treatment localized prostate carcinoma. Cancer 2005; 103(8):1615-24.
• Basaria S, Dobs AS. Hypogonadism and androgen replace- ment therapy in elderly men. Am J Med 2001;110(1): 563- 72.
• Basaria S, Lieb J, 2nd, Tang AM et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxford) 2002(1);56: 779-86.
• Stellato RK, Feldman HA, Hamdy O, Horton ES, McKin- lay JB. Testosterone, sex hormone-binding globulin and the development of type 2 diabetes in middle-aged men: pros- pevtive results from the Massachusetts male aging study. Diabetes Care 2000; 23(4):490-4.
• Schleich F, Legros JJ. Effects of androgen substition on lipid profile in the adult and aging hypogonadal male. Eur J En- docrinol 2004; 151(4): 415-24.
• Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testoste- rone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004; 89(7): 3313-8.
• Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87(2):599- 603.
• Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosteron suppression in men with prostate cancer le- ads to increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003; 104(2):195-201.
• Smith MR, Lee H, Nathan DM. Insulin sensivivty during combined androgen blockade for prostate cancer. J Clin En- docrinol Metab 2006; 91(4): 1305-8.
• Eri LM, Urdal P, Bechensteen AG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipop- roteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995; 154(1):100-4.
• Smith MR, Lee H, McGovern F, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008 ; 112(10): 2188-94.
• Salvador C, Planas J, Agreda F, Placer J, Trilla E, Lopez MA, Morote J: Analysis of the Lipid Profile and Atherogenic Risk during Androgen Deprivation Therapy in Prostate Cancer Patients. Urol Int. 2013;90(1):41-4.
• Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S : Lipoprotein profile in men with prostate can- cer undergoing androgen deprivation therapy. Int J Impot Res.2006; 18(5): 494-8.
• Keating NL, O’Malley A, Freedland SJ, Smith MR: Diabe- tes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate can- cer. J Natl Cancer Inst. 2012; 104(19): 1518-23.
• Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009; 27(21) :3452-8.
• American Diabetes Association: Standards of medical care in diabetes-2008. Diabetes Care 2008; 31 Suppl 1: 12-54.
• Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivati- on therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110(7) :1493-500.
• Studer UE, Whelan P, Albrecht W, et al. Immediate or defer- red androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: Euro- pean Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.J Clin Oncol 2006; 24(12): 1868-76.
• Shaidi NT. Androgens and erythropoesis. N Eng J Med 1973; 289: 72-80.
• Strum SB, McDermed JE, Scholz MC et al. Anemia asso- ciated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol. 1997; 79(6): 933-41.